Ignite Creation Date:
2024-05-05 @ 11:21 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00001171
Status:
COMPLETED
Last Update Posted:
2008-03-04
First Post:
1999-11-03
Brief Title:
Evaluation of Factors in Human Brain Tumors
Sponsor:
National Institute of Neurological Disorders and Stroke NINDS
Organization:
National Institutes of Health Clinical Center CC
Study Overview
Official Title:
Evaluation of Biological Immunological and Therapeutic Parameters in Brain Tumor Patients
Status:
COMPLETED
Status Verified Date:
2005-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Presently patients with primary malignant brain tumors have a life expectancy of 15 weeks following surgery unless they receive additional types of therapy chemotherapy radiotherapy andor immunotherapy Patients that receive additional therapy can increase life expectancy to 50 weeks
The statistics on the life expectancy and survival have increased efforts among researchers to develop new treatments for primary malignant brain tumors
This research project involves the growth and study of human brain tumor cells outside the body in the laboratory as part of an attempt to better understand these tumors and to develop more effective treatments for them
The statistics on the life expectancy and survival have increased efforts among researchers to develop new treatments for primary malignant brain tumors
This research project involves the growth and study of human brain tumor cells outside the body in the laboratory as part of an attempt to better understand these tumors and to develop more effective treatments for them
Detailed Description:
This protocol involves the study of human brain tumor cells outside the body in the laboratory as part of an attempt to better understand these tumors and to develop more effective therapeutic measures
Malignant primary brain tumor patients at present have a life expectancy of approximately 15 weeks following surgery unless other adjunctive measures are taken With currently available adjunctive therapy the life expectancy reaches 50 weeks
These survival data have spurred extensive efforts to develop new treatment modalities Radiation chemotherapy and immunotherapy have been mildly helpful adjuncts but their use has been largely on empirical grounds or on the basis of experimentation on animal tumor models often quite different in nature from human brain tumors
Our group has sought to develop data upon which to devise new treatment strategies for patients with malignant brain tumors
The foundation of our approach rests upon the use of in vitro studies of the cell biology of each patients tumor
It is our plan to utilize these tumors for in vitro investigation of the immunology biology biochemistry and molecular biology of brain tumors Optimal conventional therapy will be given to the patients as we seek to learn more of how the scientific information obtained can be used to help them
Malignant primary brain tumor patients at present have a life expectancy of approximately 15 weeks following surgery unless other adjunctive measures are taken With currently available adjunctive therapy the life expectancy reaches 50 weeks
These survival data have spurred extensive efforts to develop new treatment modalities Radiation chemotherapy and immunotherapy have been mildly helpful adjuncts but their use has been largely on empirical grounds or on the basis of experimentation on animal tumor models often quite different in nature from human brain tumors
Our group has sought to develop data upon which to devise new treatment strategies for patients with malignant brain tumors
The foundation of our approach rests upon the use of in vitro studies of the cell biology of each patients tumor
It is our plan to utilize these tumors for in vitro investigation of the immunology biology biochemistry and molecular biology of brain tumors Optimal conventional therapy will be given to the patients as we seek to learn more of how the scientific information obtained can be used to help them
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 79-N-0089 | None | None | None |